- Home
- MGRX vs ICU Comparison
MGRX vs ICU Comparison
Compare MGRX & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- ICU
- Stock Information
- Founded
- MGRX 2021
- ICU 2018
- Country
- MGRX United States
- ICU United States
- Employees
- MGRX N/A
- ICU 18
- Industry
- MGRX Computer Software: Prepackaged Software
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- ICU Health Care
- Exchange
- MGRX Nasdaq
- ICU Nasdaq
- Market Cap
- MGRX 25.2M
- ICU 15.9M
- IPO Year
- MGRX 2023
- ICU N/A
- Fundamental
- Price
- MGRX $2.62
- ICU $0.57
- Analyst Decision
- MGRX
- ICU
- Analyst Count
- MGRX 0
- ICU 0
- Target Price
- MGRX N/A
- ICU N/A
- AVG Volume (30 Days)
- MGRX 217.2K
- ICU 3.9M
- Earning Date
- MGRX 11-13-2025
- ICU 11-12-2025
- Dividend Yield
- MGRX N/A
- ICU N/A
- EPS Growth
- MGRX N/A
- ICU N/A
- EPS
- MGRX N/A
- ICU N/A
- Revenue
- MGRX $516,030.00
- ICU $766,000.00
- Revenue This Year
- MGRX N/A
- ICU $820.00
- Revenue Next Year
- MGRX N/A
- ICU $63.37
- P/E Ratio
- MGRX N/A
- ICU N/A
- Revenue Growth
- MGRX N/A
- ICU N/A
- 52 Week Low
- MGRX $1.32
- ICU $0.31
- 52 Week High
- MGRX $6.15
- ICU $4.28
- Technical
- Relative Strength Index (RSI)
- MGRX 59.26
- ICU 38.78
- Support Level
- MGRX $2.08
- ICU $0.61
- Resistance Level
- MGRX $2.61
- ICU $0.68
- Average True Range (ATR)
- MGRX 0.25
- ICU 0.07
- MACD
- MGRX 0.01
- ICU -0.02
- Stochastic Oscillator
- MGRX 91.65
- ICU 23.80
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.